🇺🇸 FDA
Patent

US 8765761

6-(1H-indazol-6-yl)-N-{4-[2-methyl-1-(morpholin-4-yl)propan-2-yl]phenyl}imidazo[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a syk inhibitor

granted A61KA61K31/495A61P

Quick answer

US patent 8765761 (6-(1H-indazol-6-yl)-N-{4-[2-methyl-1-(morpholin-4-yl)propan-2-yl]phenyl}imidazo[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a syk inhibitor) held by GILEAD CONNECTICUT, INC. expires Mon Jun 26 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
GILEAD CONNECTICUT, INC.
Grant date
Tue Jul 01 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 26 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
7
CPC classes
A61K, A61K31/495, A61P, A61P11/00, A61P11/02